Edward V Maytin1, Urvashi Kaw2, Muneeb Ilyas2, Judith A Mack3, Bo Hu4. 1. Department of Dermatology, Cleveland, OH 44195, United States; Department of Biomedical Engineering, Lerner Research Institute, Cleveland, OH 44195, United States; Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, United States. Electronic address: maytine@ccf.org. 2. Department of Dermatology, Cleveland, OH 44195, United States. 3. Department of Dermatology, Cleveland, OH 44195, United States; Department of Biomedical Engineering, Lerner Research Institute, Cleveland, OH 44195, United States. 4. Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH 44195, United States.
Abstract
BACKGROUND:Photodynamic therapy (PDT) is a non-scarring alternative for treating basal cell carcinoma (BCC) in patients with Basal Cell Nevus Syndrome (BCNS), also known as Gorlin syndrome. In Europe, red light (635 nm) is the predominant source for PDT, whereas in the United States blue light (400 nm) is more widely available. The objective of this study was to conduct a head-to-head comparison of blue light and red light PDT in the same BCNS patients. METHODS: In a pilot study of three patients with 141 BCC lesions, 5-aminolevulinate (20% solution) was applied to all tumors. After 4 h, half of the tumors were illuminated with blue light and the remainder with red light. To ensure safety while treating this many tumors simultaneously, light doses were escalated gradually. Six treatments were administered in three biweekly sessions over 4 months, with a final evaluation at 6 months. Tumor status was documented with high-resolution photographs. Persistent lesions were biopsied at 6 months. RESULTS:Clearance rates after blue light (98%) were slightly better than after red light (93%), with blue light shown to be statistically non-inferior to red light. Eight suspicious lesions were biopsied, 5 after red light (5/5 were BCC) and 3 after blue light (1 was BCC). Blue light PDT was reportedly less painful. CONCLUSION:Blue light and red light PDT appear to be equally safe and perhaps equally effective for treating BCC tumors in BCNS patients. Further studies to evaluate long-term clearance after blue light PDT are needed.
RCT Entities:
BACKGROUND: Photodynamic therapy (PDT) is a non-scarring alternative for treating basal cell carcinoma (BCC) in patients with Basal Cell Nevus Syndrome (BCNS), also known as Gorlin syndrome. In Europe, red light (635 nm) is the predominant source for PDT, whereas in the United States blue light (400 nm) is more widely available. The objective of this study was to conduct a head-to-head comparison of blue light and red light PDT in the same BCNS patients. METHODS: In a pilot study of three patients with 141 BCC lesions, 5-aminolevulinate (20% solution) was applied to all tumors. After 4 h, half of the tumors were illuminated with blue light and the remainder with red light. To ensure safety while treating this many tumors simultaneously, light doses were escalated gradually. Six treatments were administered in three biweekly sessions over 4 months, with a final evaluation at 6 months. Tumor status was documented with high-resolution photographs. Persistent lesions were biopsied at 6 months. RESULTS: Clearance rates after blue light (98%) were slightly better than after red light (93%), with blue light shown to be statistically non-inferior to red light. Eight suspicious lesions were biopsied, 5 after red light (5/5 were BCC) and 3 after blue light (1 was BCC). Blue light PDT was reportedly less painful. CONCLUSION: Blue light and red light PDT appear to be equally safe and perhaps equally effective for treating BCC tumors in BCNS patients. Further studies to evaluate long-term clearance after blue light PDT are needed.
Authors: Allan R Oseroff; Sherry Shieh; Noreen P Frawley; Richard Cheney; Leslie E Blumenson; Eniko K Pivnick; David A Bellnier Journal: Arch Dermatol Date: 2005-01
Authors: David M Pariser; Nicholas J Lowe; Daniel M Stewart; Michael T Jarratt; Anne W Lucky; Robert J Pariser; Paul S Yamauchi Journal: J Am Acad Dermatol Date: 2003-02 Impact factor: 11.527
Authors: Hannah C de Vijlder; Henricus J C M Sterenborg; H A Martino Neumann; Dominic J Robinson; Ellen R M de Haas Journal: Acta Derm Venereol Date: 2012-11 Impact factor: 4.437
Authors: Paige J LeValley; Bryan P Sutherland; Jennifer Jaje; Sandra Gibbs; Mark Jones; Rikhav Gala; Christopher J Kloxin; Kristi L Kiick; April M Kloxin Journal: ACS Appl Bio Mater Date: 2020-09-17